바카라 베팅 Bioscience announced on September 13th that it held a topping-out ceremony and safety prayer at the construction site of the 'Global Research & Process Development (R&PD) Center' in Songdo, Incheon. This ceremony marked the completion of the structural framework and aimed to wish for accident-free construction and future safety.

CEO Ahn commented, "The long-prepared Songdo era, aimed at establishing an innovative R&D hub that connects the world, feels closer than ever. With the completion of the Songdo center, SK Bioscience's leap as a global vaccine and biotech company will officially begin."

In 2021, 바카라 베팅 Bioscience signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZ) for a plot in the Sr14 zone of Incheon Technopark's expanded development area in Songdo. The location was chosen for its proximity to the airport, connectivity to the Andong plant, and synergies with nearby industrial complexes.

The company is investing $245 million to build the Global R&PD Center on a 30,413.8 square meter site in Songdo. Once completed, expected in the second half of 2025, the company plans to relocate its headquarters and research center from Pangyo to Songdo. The R&PD Center, which will support research through to commercial production, aims to strengthen 바카라 베팅 Bioscience's current operations while establishing a global vaccine hub to proactively address emerging infectious diseases.

A 'Pilot Plant,' designed to meet U.S. cGMP standards, will be integrated into the center to expand research in future growth areas such as cell and gene therapies (CGT), messenger RNA (mRNA), and viral vectors.

Additionally, 바카라 베팅 Bioscience's Glocalization initiative, which aims to transfer advanced R&D and production capabilities to countries with high vaccine demand but limited infrastructure, is expected to accelerate.

An SK Bioscience official stated, "Once the Songdo facility is complete, it will be capable of producing samples for preclinical, clinical, and limited commercial production. This will establish a comprehensive infrastructure linking our Andong vaccine production facility, IDT Biologika—a German CDMO company we recently acquired—and operations in the U.S., Europe, and Korea, accelerating our entry into the global market."